10 likes | 109 Vues
Study on change in LDL cholesterol levels among patients with HeFH using evolocumab or placebo administered biweekly vs. monthly. Results published in The Lancet, Oct 2014.
E N D
RUTHERFORD-2: mean change in LDL-c levels with evolocumab or placebo biweekly or monthly in HeFH Change from baseline in LDL cholesterol (%) Raal et al., The Lancet Oct 2014